Hydroxamic acid based histone deacetylase inhibitors: Present and future prospectives as anticancer agent

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 6, 2014, Pages 648-650

  Jain, Deepak K ^a   Singh, Avineesh ^a   Patel, Vijay K ^a   Sharma, Prabodh C ^b   Gupta, Arun K ^c   Sharma, Ajay K ^d   Rajak, Harish ^a  

^a GURU GHASIDAS UNIVERSITY   (India)

^b KURUKSHETRA UNIVERSITY   (India)

^c BPS Mahila Vishwavidyalaya   (India)

^d GSVM MEDICAL COLLEGE   (India)

Author keywords

Anticancer agent; Epigenetics; Histone deacetylases; Hydroxamic acid

Indexed keywords

6 (1, 3 DIOXO 1H, 3H BENZO [DE] ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ABEXINOSTAT; ANTINEOPLASTIC AGENT; BELINOSTAT; DACINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMIDAZOLE; OXAMFLATIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

CUTANEOUS T CELL LYMPHOMA; DRUG CLASSIFICATION; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN; HYDROGEN BOND; LINKER DOMAIN; METAL BINDING; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; REVIEW; STRUCTURE ACTIVITY RELATION; SURFACE RECOGNITION DOMAIN; X RAY CRYSTALLOGRAPHY;

EID: 84904044208     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429(6990): 457-463.
2. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003; 3(4): 344-351.
3. Venugopal B, Evans TRJ. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2011; 18: 1658-1671.
4. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-168.
5. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int J Oncol 2004; 25(6): 1509-1519.
6. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23(17): 3971-3993.
7. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528.
8. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22(22): 4632-4642.
9. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40: 1-13.
10. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, et al. Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Med Res Rev 2005; 25: 261-309.
11. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A, Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008; 10: 395-398.
12. Roth SY, Denu JM, Allis DC. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
13. Hodawadekar SC, Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: Structure, mechanism and implications for effector design. Oncogene 2007; 26: 5528-5240.
14. Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 2007; 11: 835-851.
15. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
16. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Res 2007; 17: 195-211.
17. North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 2004; 5: 224-228.
18. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 2009; 10: 32-42.
19. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262(2): 75-83.
20. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107(2): 137-148.
21. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107(2): 149-159
22. Dutnall RN, Pillus L. Deciphering NAD-dependent deacetylases. Cell 2001; 105: 161-164.
23. Marks PM, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-168.
24. Kyrylenko S, Kyrylenko O, Suuronen T, Salminem A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci 2003; 60: 1990-1997.
25. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 2007; 5: 981-989.
26. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHAinhibitors. Nature 1999; 401: 188-193.
27. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006; 126: 257-268.
28. Fouche KF, RouxHJ, Phillips F. Complex formation of Zr (IV) and Hf (IV) with hydroxamic acids in acidic solutions. J Inor Nucl Chemi 1970; 32: 1949-1962.
29. Agrawal YK. Hydroxamic acids and their metal complexes. Russ Chem Rev 1979; 48: 948-963.
30. Barocas A, Baroncelli F, Biondi GB, Grossi G. The complexing power of hydroxamic acids and its effect on behaviour of organic extractants in the reprocessing of irradiated fuels-II: The complexes between benzohydroxamic acid and thorium, uranium (IV) and plutonium (IV). J Inor Nucl Chemi 1996; 28: 2961-2967.
31. Yujia D, Yan G, Michael C, Lori J, Jun G, Marcotte PA et al. A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett 2003; 13: 3817-3820.
32. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003; 46: 5097-5116.
33. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-17179.
34. Tsuji N, Kobayashi K, Nagashima Y, Wakisaka K, Koizumi J. A new antifungal antibiotic, trichostatin. J Antibiot 1976; 29: 1-6.
35. Kelly WK, O Conor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-3931.
36. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, et al. Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006; 7: 257-261.
37. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-39.
38. Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 2004; 13: 21-38.
39. Marson CM, Mahadevan T, Dines J, Sengmany S, Morrell JM, Alao JP, et al. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Biorg Med Chem Lett 2007; 17: 136-141.